NEO Overview

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is14.00 USD with a low forecast of 12.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neogenomics Inc revenue for the last quarter amounts to 188.00M USD, increased 11.90 % YoY.

Neogenomics Inc. EPS for the last quarter amounts to -0.21 USD, increased 50.00 % YoY.

Neogenomics Inc (NEO) has 2200 emplpoyees as of January 30 2026.

Today NEO has the market capitalization of 2.00B USD.